Skinive has raised $280K in total across 1 funding round.
Skinive's investors include Rockstart.
Skinive is an Amsterdam-based healthtech company founded in 2020 that develops AI-powered dermatological solutions, primarily a smartphone app and API for analyzing skin conditions.[1][2][3] Its products include consumer-facing apps (Skinive app), professional tools (Skinive MD app), and Skinive.Cloud API, which detect over 50 skin issues like warts, psoriasis, acne, benign formations, pre-cancerous lesions, and skin cancers including melanoma, BCC, and SCC, while providing personalized recommendations and remote monitoring.[1][4][5] Skinive serves individuals at home, primary care professionals, dermatologists, and B2B partners such as telemedicine providers, insurers, pharma companies, and beauty apps, solving the problem of accessible, early skin disease detection to reduce unnecessary specialist visits, lower costs, and enable proactive monitoring via photo analysis.[2][4][5]
The platform's CE-marked Class I medical software, with ISO 13485 compliance, GDPR, and HIPAA adherence, boosts detection rates, facilitates telehealth, and integrates into digital health ecosystems for instant assessments trained on millions of images.[3][4][5] Growth momentum includes global adoption, partnerships like with Italy's DaVinci Salute (part of UNIPOL Group) for remote care, and expansion into enterprise solutions amid rising demand for AI dermatology.[2]
Skinive emerged in 2020 from Skinive Holding B.V. in Amsterdam, Netherlands, as a response to the need for convenient, AI-driven skin health screening without always requiring in-person visits.[1][3][5] While specific founders are not detailed in available sources, CEO Kirill Sokol has been vocal about its mission to simplify skincare access, positioning the AI as a "search engine for your skin" where users snap photos for plain-language insights on conditions resolvable with over-the-counter products.[2] Early traction built on clinically proven technology, earning CE marking as Class I medical software and ISO 13485 certification, with apps trusted by dermatologists worldwide.[2][3][5]
Pivotal moments include launching consumer and pro apps, developing the Skinive.Cloud API for third-party integration, and forming strategic alliances like the 2025 partnership with DaVinci Salute to enhance remote dermatology in Europe.[2] The related Stichting Skinive Foundation (KVK 8621421) has driven awareness via initiatives like #SkiniveChallenge, promoting skin monitoring while the holding company advances AI development.[5]
Skinive rides the AI-in-healthcare wave, specifically democratizing dermatology amid smartphone ubiquity and telehealth boom post-pandemic, where early skin cancer detection can cut treatment costs and improve outcomes.[1][2][4] Timing aligns with regulatory progress for AI medtech (e.g., CE marking) and market forces like aging populations, rising skin cancer rates, and digital health investments favoring scalable screening over clinic dependency.[3][5] It influences the ecosystem by enabling B2B integrations that enhance apps from beauty to insurance, fostering proactive care models and reducing healthcare burdens—competing with players like Skin Analytics (NHS-focused) and MetaOptima (workflow tools) through consumer accessibility and global reach.[1]
Skinive is poised for expansion via API partnerships and enterprise adoption, potentially targeting U.S. FDA clearance or deeper Asia/EU penetration as AI dermatology matures.[2][4] Trends like multimodal AI (combining images with patient data) and wearable integrations will shape its path, amplifying influence in preventive health ecosystems. As remote care normalizes, Skinive could redefine accessible dermatology, empowering users from homes to clinics—turning smartphone snapshots into lifelines for skin health.
Skinive has raised $280K across 1 funding round. Most recently, it raised $280K Seed in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $280K Seed | Rockstart |
